

Successful Placement of SPP Shortfall

Highlights

- Share Purchase Plan (SPP) shortfall placed to institutional and sophisticated investors
- Total of \$1,500,000 raised under the SPP and shortfall placement
- Total of \$3,905,000 raised overall via placement and SPP
- Funds to be used to strengthen the Company's Balance Sheet and to accelerate the commercial rollout of its remote monitoring maternity care platform

HeraMED Limited (ASX: HMD) ("HeraMED" or the "Company"), a medical technology company leading the digital transformation of maternity care with its proprietary remote monitoring maternity care platform, is pleased to announce that it has placed the shortfall from the SPP of \$1,267,000 to a range of institutional and sophisticated investors ("**Shortfall Placement**").

The Company originally raised \$233,000 through its SPP with the allotment of 2,588,879 shares to existing shareholders. Today, a total of 15,000,000 shares were placed to investors who participated in the Shortfall Placement (raising a total of \$1,350,000). This shortfall balance includes an additional 933,213 (\$82,999) shares above the original Shortfall Placement ("**Shortfall Shares**"). The Shortfall Placement was approved by shareholders at the recent annual general meeting held on 14 July 2020. It is anticipated that the Shortfall Shares will be allotted Monday, 10 August 2020.

The funds raised to date will be used to strengthen the Company's Balance Sheet and to accelerate the commercial rollout of its proprietary digital pregnancy monitoring platform, HeraCARE.

CEO and Co-founder Mr David Groberman said: "I am delighted with the support we have received from both new and existing investors and the successful completion of the shortfall placement ensures we are well placed to continue to execute our commercialisation strategy.

"COVID-19 presents a unique opportunity to fast-track adoption of digital health and maternity care, and HeraMED is well-placed to deliver high-quality pre and post-natal care to expectant mothers globally.

"As announced, we have recently achieved several key strategic milestones including securing clinical studies in the US and Australia which are ongoing. Supported by a strengthened balance sheet, HeraMED is now well placed to expand our network of collaborations and partnerships in strategically important locations, to secure further validation and ultimately to drive adoption.

"The growing demand for innovative remote monitoring and maternity telehealth solutions continues with interest from leading healthcare providers globally in relation to both HeraCARE and HeraBEAT Plus.

Henslow Pty Ltd acted as lead manager to the Placement.

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited
CEO and Co-Founder
David Groberman
M: +972 52 6991188
E: David@hera-med.com

Company Secretary
Jonathan Hart
T: +61 2 8379 2961
E: Jonathan@hera-med.com

Media Enquiries
Melissa Hamilton
Media & Capital Partners
M: +61 4 1775 0274
E: Melissa.hamilton@mcpartners.com.au

About HeraMED Limited (ASX: HMD):

HeraMED is an innovative medical technology company leading the digital transformation of maternity care by revolutionising the pre and postnatal experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.

About HeraCARE

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.